Varicella Zoster Virus, Human, IgG, BioAssay(TM) ELISA Kit (VZV)

The United States Biological Varicella Zoster Virus, Human, IgG, BioAssay(TM) ELISA Kit is intended for the detection and quantitative determination of IgG antibody to VZV in sample serum. Individual serum specimens may be used for the determination of immune status. Paired serum, acute and convalescent, may be used to demonstrate seroconversion or a significant rise in antibody level.\n\nVaricella, more commonly known as chickenpox, and herpes zoster are known clinical manifestations of infection with varicella-zoster virus (VZV).\n\nChicken pox, the clinical syndrome usually produced as a result of the primary infection with VZV, is a highly contagious disease characterized by widely spread vesicular eruptions and fever. The disease is endemic in the U.S. and most commonly affects children from five to eight years of age, although adults and younger children, including infants, may develop chickenpox. Every two to five years, usually in the winter or spring, the number of cases increases to epidemic levels. VZV infection during early pregnancy has been implicated in congenital anomalies in rare cases. When infection occurs at term, life-threatening infections can occur in the neonate.\n\nHerpes zoster is mainly a disease of adults, with most cases appearing in samples fifty years or older. Evidence suggests that this manifestation of VZV infections results from a reactivation of virus which has remained latent in the sensory spinal ganglia after the primary infection rather than a reintroduction of the virus into the host. Fever and painful localized vesicular eruptions of the skin along the distribution of the involved nerves are the most common clinical symptoms of the condition. Zoster lesions can be mistaken for the similar lesions produced by herpes simplex virus in which recurrences are common. However, recurrences of herpes zoster are extremely rare.\n\nDetermination of the immune status of high risk individuals who are exposed to VZV, the screening for potential donors of Varicella-zoster immunoglobulin, and the diagnosis of VZV infected individuals (both pre- and postnatal) is usually accomplished by serological testing. \n\nThe various methods for the detection of VZV antibodies in a sample's serum include indirect immunofluorescence, neutralization, complement fixation and fluorescent antibody to membrane antigen (FAMA). FAMA is generally considered the most sensitive and specific of the methods, yet requires the use of cell culture which is cumbersome to perform. Clinical and correlation studies performed by Shehab and Brunell indicate that the ELISA methodology may be as sensitive and perhaps more specific than the FAMA assay. The sensitivity, specificity, and reproducibility of ELISAs are comparable to other serological tests for antibody, such as immunofluorescence, complement fixation, hemagglutination and radioimmunoassays.\n\nThe United States Biological Varicella Zoster Virus, Human, IgG, BioAssay(TM) ELISA Kit provides all the necessary reagents for the rapid quantitative determination of VZV IgG antibody in sample serum.\n\nKit Components:\n1. Microtiter Plate, Varicella-zoster virus antigen (inactivated): 1 X 96 wells\n2. Serum Diluent: 1X30ml\n3. Calibrator (sample serum or defibrinated plasma): 1X400ul\n4. Positive Control: 1X400ul\n5. Negative Control: 1X400ul\n6. IgG (HRP) Goat x human: 1X16ml\n7. Tetramethylbenzidine (TMB): 1x15ml \n8. Wash Buffer, 20X: 1x50ml\n9. Stop Solution: 1x15ml (1N H2SO4)\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2100-29

Size

1Kit

Applications

ELISA

Reactivities

Hum

References

1. Weller, T.H. 1965. Varicella-Herpes Zoster Virus. In: Viral and Rickettsial Infections of Man, 4th edition. F.L. Horstall, Jr. and I.Tamm, eds. pp 915-925. 2. Young, N.A. 1976. Chickenpox, Measles and Mumps. In: Infectious Diseases of the Fetus and Newborn Infant. J.S. Remington and J.O. Klein, eds.W.B. Saunders Company, Philadelphia. pp. 521-583. 3. Ray, C.G. 1977. Chickenpox (Varicella) and Herpes Zoster. In: Harrison's Principles of Internal Medicine. G.W. Thorn, et al., ed. Mcgraw-Hill, New York. pp. 1020-1023. 4. Gershon, A.A. 1975. Varicella in Mother and Infant. Problems Old and New. In: Infections of the Fetus and the Newborn Infant. S. Krugman and A.A. Gershon, eds. Alan R. Liss, Inc., New York, N.Y. 5. Williamson, A.P. 1975. The Varicella-Zoster Virus in the Etiology of Severe Congenital Defects. A Survey of Eleven Reported Instances. Clin. Pediatr. 14: 533-559. 6. Meyers, J.D. 1974. Congenital Varicella in Term Infants: Risk Reconsidered. J. Infect. Dis. 129: 215-217. 7. Adelstein, A.M. and J.W. Donovan. 1972. Malignant Disease in Children Whose Mothers Had Chickenpox, Mumps, or Rubella in Pregnancy. Brit Med. J. 4: 629-631. 8. Schmidt, N.J. 1985. Varicella-Zoster Virus. In: Manual of Clinical Microbiology, 4th edition. E.H. Lennette, A. Balows, W.J. Hausler, H.J. Shadomy, eds. American Society of Microbiology (ASM), Washington, DC. pp.720-727. 9. Brunell, P.A. and Z.M. Shehab. 1986. Varicella-Zoster. In: Manual of Clinical Laboratory Immunology, 3rd edition. N.R. Rose, H. Friedman and J.L. Fahey, eds. ASM, Washington, DC. pp. 502-503. 10. Schmidt, N.J., E. H. Lennette, J.D. Woodie and H.H. Ho. 1985. Immunofluorescent Staining in the Laboratory Diagnosis of Varicella-Zoster Virus Infections. J. Lab and Clin. Med. 66: 403-411. 11. Lyerla, H.C. and F.T. Forrester. 1978. Varicella-Zoster Virus. In: Immunfluorescence Methods in Virology. U.S. Department of Health, Education, and Welfare. pp. 162-163. 12. Weller, T.H. et al., Biol. Med. 87: 789-794. 13. Williams, V., et al., J. Inf. Dis. 130: 669-672. 14. Shehab, Z. and P.A. Brunell. 1983. Enzyme-Linked Immunosorbent Assay for Susceptibility to Varicella. J. Infect. Dis. 148: 472-476. 15. Engvall, E., and P. Perlman. 1971. Enzyme-Linked Immunosorbent Assay (ELISA) Quantitative Assay of Immunoglobulin G. Immunochemistry. 8: 871- 874. 16. Engvall, E. et al., Brugge Oxford, Pergamon Press. pp. 553-556. 17. Engvall, E., K. and P. Perlmann. 1971. Enzyme-Linked Immunosorbent Assay. II. Quantitative Assay of Protein Antigen, Immunoglobulin-G, By Means of Enzyme- Labelled Antigen and Antibody-Coated tubes. Biochem. Biophys. Acta. 251: 427-434. 18. Van Weeman, et al., FEBS Letter. 15232-235. 19. Bakerman, S. 1980. Enzyme Immunoassays. Lab. Mgmt. August: 21-29. 20. Cappel, R., et al., Arch. Virol. 58: 253-258. 21. Engvall, E. and P. Perlman. 1972. Enzyme-Linked Immunosorbent Assay, ELISA. III. Quantitation of Specific Antibodies by Enzyme- Labelled Anti- Immunoglobulins in Antigen- Coated Tubes. J. Immunol. 109: 129-135. 22. Schauf, V. and M. Tolpin. 1984. Varicella-Zoster Virus. In: Textbook of sample Virology, Belshe, ed. PSG Publishing, Littleton, MA. pp. 829-851. 23. Schmidt, N.J., et al., J. Gen. Virol. 4: 321-28. 24. Fenner, F., and D.O. White. 1976. In: Medical Virology. Academic Press. p. 308. 25. Arvin, A.M., C.M. Koropchak, and A.C. Wittek. 1983. Immunologic Evidence of Reinfection with Varicella- Zoster Virus. J. Infect. Dis. 148: 200-205. 26. Gershon, A.A., et al., Ped. Infect. Dis. 1: 164-167. 27. Gallo, D et al., J. Clin. Micro. 14: 539-543. 28. Preissner, C.M., et al., J. Clin. Micro. 6: 373-376. 29. Grose, C.F., et al., J. Infect. Dis. 139: 432-437. 30. Rawls,W.E. 1979. Herpes Simplex Virus Types 1 and 2 and Herpes Virus Simiae, Chapter 11. In: Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, 5th edition. E.H. Lennette and N.J. Schmidt, eds. American Public Health Association, Inc., Washington, D.C. pp. 337-338. 31. Cremer, N.E., et al., J. Clin. Micro. 20: 468-472. 32. Weller, T.H. 1979. Varicella and Herpes zoster, Chapter 12. In: Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, 5th edition. E.H. Lennette and N.J. Schmidt, eds. American Public Health Association, Inc., Washington, D.C. pp.375-398. 33. Arvin, A.M., et al. 1986. Early Immune Response in Healthy and Immunocompromised Subjects with Primary Varicella-Zoster Virus Infection. J. Infect. Dis. 154: 422-29. 34. Bogger-Goren, S. et al. 1982. Antibody Response to Varicella Zoster Virus After Natural or Vaccine-induced Infection. J. Infect. Dis. 146: 260-65.35. Brunell, P.A., et al. 1975. Varicella-Zoster Immunoglobulins During Varicella, Latency, and Zoster. J. Infect. Dis. 132: 49-54. 36. CDC-NIH Manual. 1993. Biosafety in Microbiological and Biomedical Laboratories, 3rd edition. U. S. Dept. of Health and sample Services, Public Health Service. pp. 18-24.37. National Committee for Clinical Laboratory Standards. 1990. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture Approved Standard. NCCLS Publication H18-A.38. NCCLS. 1991. National Committee for Clinical Laboratory Standard. Internal Quality Control Testing: Principles & Definition. NCCLS Publication C24- A. 39. http://www.cap.org/html/ftpdirectory/checklistftp.html. 1998. Laboratory General - CAP (College of American Pathology) Checklist (April 1998). pp 28-32. 40. NCCLS. 1997. National Committee for Clinical Laboratory Standard. Preparation and Testing of Reagent Water in the Clinical Laboratory. NCCLS Publication C3- A3.